Treatment with dapirolizumab pegol is better than a placebo at controlling disease activity in people with systemic lupus erythematosus (SLE), according to new results from a Phase 3 clinical trial.
Columnist Marisa Zeppieri welcomes the season of holiday food while offering tips to get people with lupus through any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback